Kurve Therapeutics

What Kurve Therapeutics does

Kurve Therapeutics, Inc. (formerly Kurve Technology, Inc.) is a Lynnwood, Washington-based clinical-stage medtech company founded in 2001 that develops non-invasive, intranasal drug delivery systems targeting central nervous system disorders. Its core platform is Controlled Particle Dispersion (CPD), a patented technology that generates a focused, turbulent aerosol flow to navigate the nasal cavity and access the olfactory mucosa, bypassing the blood-brain barrier to deliver medication directly to the brain. The hardware manifestation is the ViaNase Intelligent Delivery Device — a battery-powered, pocket-sized, one-button atomizer — paired with proprietary drug formulations including an intranasal insulin candidate for Alzheimer's disease and mild cognitive impairment. Internal and clinical data report up to 30x more brain delivery than IV infusion, with one head-to-head study reporting 3,000% greater delivery; the platform is supported by 18 peer-reviewed publications and five double-blind, placebo-controlled Phase II studies, with Phase III readiness in three disease states.

The business model combines a B2B technology-licensing and drug-formulation-collaboration model (targeting CNS researchers at academic institutions such as Johns Hopkins, Harvard, Karolinska, and Wake Forest, as well as pharmaceutical companies developing monoclonal antibodies and larger peptides) with proprietary drug commercialization upon regulatory approval. The company is raising up to $50 million through a Regulation A+ equity crowdfunding offering via Rialto Markets to fund Phase III trials. Named partners include Orgenesis for glioblastoma and Hospital Infantil Universitario Niño Jesús (Madrid) for cell-based therapy manufacturing, with international clinical presence in the U.S., Sweden, and the Netherlands. Leadership is a four-person executive team led by founder/CEO Marc Giroux, the lead or sole inventor on Kurve's IP.

Revenue is not disclosed and Kurve operates as pre-revenue; income is expected to derive from future licensing royalties, one-time technology licenses, and proprietary drug sales rather than current operations. Marketing is conducted primarily through the corporate website, peer-reviewed publications, industry conferences (e.g., LSI USA '23), press releases, a dedicated Nasal Drug Delivery blog, and a multi-platform social media presence.

Name

Kurve Therapeutics

Legal name

Kurve Therapeutics, Inc.

Website

https://kurvetx.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

11–50 employees

Short description

Kurve Therapeutics is a Lynnwood, Washington-based clinical-stage medtech company developing the patented ViaNase device and Controlled Particle Dispersion (CPD) technology for non-invasive, intranasal nose-to-brain drug delivery to treat neurodegenerative diseases such as Alzheimer's, Parkinson's, and glioblastoma.

Ownership category

akta.pro rank

Product category

Intranasal Drug Delivery

NAICS

Surgical and Medical Instrument Manufacturing (339112), Pharmaceutical Preparation Manufacturing (325412), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834)

akta.pro primary industry

Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL), Drug Delivery Connectivity, Sensors & Digital Add-Ons (Smart Caps/Companion Apps) (HLAHAIAM)

Keywords

• Intranasal drug delivery
• CNS therapeutics
• Neurodegenerative disease treatment
• Medtech device platform
• Blood-brain barrier delivery

Headquarters

HQ city

Lynnwood

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Technology Licensing: Kurve licenses its CPD technology and ViaNase device to pharmaceutical companies developing CNS drugs, enabling them to reformulate existing or new therapies for intranasal delivery to bypass the blood-brain barrier.
2. Drug Formulation Services: The company develops proprietary drug formulations for neurodegenerative diseases and may commercialize these as branded therapies upon successful clinical trials and regulatory approval.
3. Equity Crowdfunding: The company is raising capital through Regulation A+ equity crowdfunding, offering shares to public investors starting at $580 for 100 shares.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

Kurve Therapeutics develops and commercializes a patented Controlled Particle Dispersion (CPD) intranasal drug delivery technology delivered via the ViaNase Intelligent Delivery device, enabling non-invasive nose-to-brain delivery that bypasses the blood-brain barrier. The company pairs the CPD platform with proprietary drug formulations (including intranasal insulin) for the treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's, and related CNS disorders.

Product overview

Kurve Therapeutics offers a next-generation medtech platform centered on the ViaNase Intelligent Delivery device, which incorporates the patented Controlled Particle Dispersion (CPD) technology. This hardware-software combination enables non-invasive nasal drug delivery directly to the brain, bypassing the blood-brain barrier. The company pairs its delivery technology with proprietary drug formulations including intranasal insulin for neurodegenerative diseases. The CPD technology serves as the core platform enabling delivery of various pharmaceutical formulations, while the ViaNase device is the hardware interface for patient administration. Kurve has developed multiple formulations including intranasal insulin, with ongoing development for additional therapeutic agents for conditions including Alzheimer's, Parkinson's, and glioblastoma.

Differentiator

Problem solved

Functional benefit

Brands

• ViaNase™ Intelligent Delivery: The company's core drug delivery device using Controlled Particle Dispersion (CPD) technology for intranasal drug delivery to bypass the blood-brain barrier

Products and services

• ViaNase Intelligent Delivery Device A nasal drug delivery device that uses Controlled Particle Dispersion (CPD) technology to deliver medication directly to the brain via the olfactory mucosa, bypassing the blood-brain barrier. Designed for pharmaceutical partners, academic researchers, and clinical trial use.
• Kurve Intranasal Insulin Product An insulin formulation designed for intranasal delivery via the ViaNase device for treatment of Alzheimer's disease, mild cognitive impairment, and other neurodegenerative conditions.

Quantifiable outcome

• 30x more medication delivered to brain than IV infusions
• +4 more outcomes

Named customers10 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core.

• OrgenesiscoreStrategic or Co-development Partner · 20 December 2022Collaboration between Kurve and Orgenesis for preclinical study on cell-based oncolytic virus bearing product for glioblastoma treatment. Orgenesis provides mesenchymal stem-cell-based product while Kurve provides its patented CPD intranasal drug delivery technology to bypass the blood-brain barrier. The study demonstrated over 50% tumor reduction in a murine glioblastoma model.
• Hospital Infantil Universitario Niño JesúscoreStrategic or Co-development Partner · 20 December 2022Involved in the Orgenesis collaboration, Hospital Niño Jesús in Madrid performs clinical-grade manufacturing using Orgenesis Mobile Processing Units and Lab (OMPUL) for the cell-based product intended for intravenous administration, with plans for future intranasal delivery using Kurve's technology.
• Harvard Medical SchoolcoreTechnology or IntegrationRecent and ongoing collaboration with Harvard for clinical research on cognition in diabetics using Kurve's intranasal drug delivery technology.
• Johns HopkinscoreTechnology or IntegrationOngoing collaboration with Johns Hopkins for multiple clinical trials including Alzheimer's Disease research, Multiple Sclerosis cognition studies, Neuropathic Pain research, and selective CNS uptake studies. Kurve's technology featured in peer-reviewed publications.
• Karolinska InstitutecoreTechnology or IntegrationRecent and ongoing collaboration with Karolinska Institute in Sweden for mood and anxiety disorders clinical research using Kurve's intranasal drug delivery technology.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Emerging players

• AeroFact: AeroFact is developing intranasal insulin for Alzheimer's disease using a similar delivery approach to Kurve's ViaNase. It is an emerging player directly overlapping in the intranasal insulin for CNS disease niche.

Direct peers

• OptiNose: OptiNose develops intranasal drug delivery devices targeting CNS and respiratory conditions using proprietary breath-powered technology. It is a direct competitor in the nasal-to-brain / targeted nasal delivery space with FDA-approved products, making it the closest commercial-stage comparable to Kurve's ViaNase platform.
• Impel Pharmaceuticals: Impel (now part of AbbVie/formerly) developed the POD technology for intranasal drug delivery targeting the upper nasal cavity, with a CNS focus including acute migraine (Trudhesa). It is a direct peer in nose-to-brain delivery and CNS therapeutics commercialization.

Broad incumbents

• Aptar Pharma: Aptar Pharma is a global leader in nasal drug delivery devices and dispensing systems, supplying a broad portfolio of nasal spray pumps and devices to pharma partners. As a broad incumbent, it competes for the same licensing/partnership opportunities Kurve targets, though with a much wider device portfolio.
• Nemera: Nemera is a drug delivery device manufacturer with a significant intranasal delivery portfolio including electronic and preservative-free systems. As a broad incumbent, it competes with Kurve in nasal device partnerships for CNS and respiratory indications.
• Becton Dickinson (BD): BD Pharmaceutical Systems is a major supplier of drug delivery devices including prefilled syringes, autoinjectors, and nasal systems. As a broad incumbent, BD represents the type of strategic acquirer or large partner that Kurve would likely need for commercialization.
• Biogen: Biogen is a major CNS-focused biopharmaceutical company with established Alzheimer's, MS, and ALS programs. It represents both a potential strategic acquirer/partner for Kurve and the type of established incumbent whose delivery modalities Kurve's platform would compete with.
• West Pharmaceutical Services: West Pharmaceutical Services provides drug delivery device components and injectable/inhalation delivery systems to pharma and biotech. As a broad incumbent in drug delivery, it is comparable to Kurve's platform business in serving pharma formulation and delivery needs.

Regional players

• Cassava Sciences: Cassava Sciences (US) develops treatments for Alzheimer's disease and CNS disorders. While it uses oral rather than intranasal delivery, it is a relevant comparable in late-stage CNS drug development, market size, and the binary trial readout dynamics Kurve faces.
• BioDelivery Sciences International: BDSI developed and commercialized specialty pharmaceutical products using novel delivery technologies, particularly in pain and CNS. It is comparable to Kurve in combining proprietary delivery technology with branded drug formulations, and demonstrates the typical small-cap commercial trajectory.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/KurveTX
• YouTubeyoutube.com/@kurvetherapeutics9467
• Facebookfacebook.com/KurveTherapeutics
• LinkedInlinkedin.com/company/kurve-therapeutics-inc
• Instagraminstagram.com/kurvetherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds6 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kurve Therapeutics